{"entity":{"id":"dan-311","kind":"drug","name":"DAN-311","aka":[],"tldr":"DAN-311 is an experimental targeted high-capacity drug conjugate from Dantari, in preclinical development for HER2-positive breast cancer and HER2-low breast cancer; its current status is not stated.","summary":"DAN-311 is a targeted high-capacity drug conjugate from Dantari. A drug conjugate on the T-HDC platform for HER2-positive and HER2-low breast cancer. Its furthest stage is preclinical development, for HER2-positive breast cancer and HER2-low breast cancer. No clinical trial naming it is registered on ClinicalTrials.gov. Planned to enter the clinic in late 2023 (Dec 2022 coverage); no registry study names DAN-311. It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"Dantari: biospace.com","url":"https://www.biospace.com/dantari-launches-with-47m-to-make-better-adcs"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["dantari"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"DAN-311","modality":"Targeted high-capacity drug conjugate","mechanism":"A drug conjugate on the T-HDC platform for HER2-positive and HER2-low breast cancer.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/dan-311/","neighbours":{"company":[{"id":"dantari","kind":"company","name":"Dantari","route":"/companies/dantari/"}]}}